Filing summary
Entity mismatch: The supplied filing is Onconova Therapeutics, Inc.’s Form 10-Q, not a filing for Traws Pharma, Inc. It covers the quarter and nine months ended September 30, 2013, and was signed November 14, 2013.
Business context
Onconova was a clinical-stage biopharmaceutical company developing cancer drug candidates. Its pipeline included three clinical-stage candidates and six preclinical programs. Rigosertib was its lead candidate, with development and commercialization partners Baxter in Europe and SymBio in Japan and Korea; Onconova retained rights elsewhere, including the United States.
Financial performance and liquidity
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Revenue | $1.1 million | $42.8 million | $2.8 million | $43.2 million |
| Operating expenses | $21.2 million | $35.9 million | $50.5 million | $55.2 million |
| Net loss | $20.5 million | $1.4 million | $47.9 million | $19.7 million |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $(44.3) million | $29.4 million |
- At September 30, 2013, cash and cash equivalents were $76.6 million and marketable securities were $40.0 million, totaling $116.6 million. Working capital was $107.1 million.
- Total assets were $122.7 million and total liabilities were $28.9 million. The filing reports no outstanding preferred stock after the IPO conversion and does not report borrowings or debt outstanding at September 30, 2013.
- The company raised $79.8 million net in its July 2013 IPO. Cash and cash equivalents declined by $4.9 million over the first nine months as operating and investing outflows were largely offset by IPO proceeds.
- Gross margin is not presented; the filing does not provide a clear value for it.
Material changes and unusual items
- Revenue fell sharply year over year because $42.6 million of the $50.0 million Baxter upfront payment was recognized in the comparable 2012 period. In 2013, revenue primarily reflected ongoing collaboration performance and SymBio-related revenue.
- Despite lower operating expenses, nine-month net loss widened by $28.3 million. The prior-year comparison included substantially higher collaboration revenue; 2013 also had higher clinical-trial spending and income tax expense.
- Research and development expense fell 10% for the nine-month comparison to $38.1 million. The decrease included the absence of a $12.5 million Temple University milestone payment made in 2012, partly offset by increased clinical-trial costs and headcount.
- Interest expense fell to $3,000 for the first nine months from $8.6 million in 2012, following conversion of promissory notes into preferred stock in July 2012.
- The IPO converted all outstanding preferred stock into common stock. Common shares outstanding rose to 21.4 million at September 30, 2013 from 2.6 million at year-end 2012.
Outlook, risks and contingencies
- Management expected operating losses and cash expenditures to continue, with spending driven by rigosertib trials and other development programs. It stated that existing resources were expected to fund operations for at least the next 12 months, while also anticipating substantial additional financing needs.
- Management expected top-line overall-survival results from the pivotal higher-risk MDS rigosertib trial in December 2013 or the first quarter of 2014, and a planned interim futility and safety analysis in the pancreatic-cancer trial in December 2013. These were expectations, not reported results.
- Key risks included clinical and regulatory uncertainty, the need for future capital, reliance on third-party manufacturers and suppliers, and dependence on collaborators for development and commercialization. The company disclosed reliance on separate contract manufacturers for rigosertib’s active ingredient and IV and oral formulations, with no alternate suppliers yet identified.
- Disclosure controls were assessed as ineffective because of an unremediated material weakness in financial reporting staffing and expertise. The company described hiring finance personnel and planned further remediation, but could not assure that the weakness would be resolved.
- The filing states there were no material legal proceedings and no material non-cancelable purchase commitments. It also describes potential future milestone, royalty and other obligations, including payments to Temple University and The Leukemia and Lymphoma Society.
Important facts for investors to verify
- Confirm that this is the intended issuer: the filing is for Onconova Therapeutics, Inc., ticker ONTX, not Traws Pharma, Inc.
- Check subsequent disclosures for the rigosertib trial results and whether the expected timing or development plans changed.
- Assess cash runway against ongoing trial spending, future financing requirements and the availability of contingent collaboration milestones.
- Review whether the disclosed material weakness in internal controls was remediated and whether disclosure controls became effective.
- Monitor manufacturing scale-up, cGMP compliance and the availability of backup suppliers for rigosertib.